The unique pharmacology of buprenorphine that includes partial MOR agonism and KOR antagonism likely contributes to its potential therapeutic effects, where there is strong support for KOR antagonism in alleviating anhedonia and depression. The gene discussed is OPRK1; the disease is major depressive disorder.